Nonetheless FDA approved only three new treatments in the last 20 years for pancreatic cancer (gemcitabine, erlotinib, nab-paclitaxel), of which the only targeted agent is the EGFR inhibitor erlotinib. This evidence concerns the gene EGFR and familial pancreatic carcinoma.